Background: Traumatic ulcer is a lesion formed by a local tissue damage due to trauma on epithelial layer. Vascular Endothelial Growth Factor (VEGF) plays an important role in wound healing, especially in angiogenesis. Golden sea cucumber (Stichopus hermanni) is believed to accelerate the wound healing process. Objective: To prove that golden sea cucumber extract can increase VEGF expression in oral mucous membrane traumatic ulcer in rat. Method: S. hermanni extract was prepared by freeze-dry method, then an extract was made using PEG 400 or PEG 4000 at 40% and 80% concentrations, respectively, and applied to the animal’s oral wounds. The animals were divided into three groups: control; 40% S. hermanni extract gel; and 80% S. hermanni extract gel. The ulcers that formed on day 3 were rubbed gently with S. hermanni extract gel. After being sacrificed on day 4, sample tissues from the lower lips were prepared for histopathology to count the number of VEGF expression. The results were analyzed using the One-Way ANOVA statistical test. Results: A significant increase in the VEGF expression of 80% concentration S. hermanni extract gel was found compared with those in the control group (p=0.00). Conclusion Golden sea cucumber extract (Stichopus hermanni) gel increased the VEGF expression in oral mucous traumatic ulcer.
Vascular Endothelial Growth Factor A

No abstract available.
Vascular Endothelial Growth Factor A*

No abstract available.
Asthma* ; Vascular Endothelial Growth Factor A*

No abstract availalbe.
Angiogenesis Inducing Agents* ; Vascular Endothelial Growth Factor A

No abstract available.
Hypertension ; Kidney ; Vascular Endothelial Growth Factor A

No Abstract Available.
Cell Line* ; Humans* ; Vascular Endothelial Growth Factor A*

No Abstract Available.
Cell Line* ; Humans* ; Vascular Endothelial Growth Factor A*

Vascular endothelial growth factor (VEGF) and inflammation. VEGF-A circulates normally in the body and is essential in endothelial cell growth. In the pathological state in the eye, hypoxia increases VEGF-A, promotes growth of neovascularization and accelerates the breakdown of blood-retinal barrier and build-up of fluid in or under the neurosensory retina and retinal pigment epithelium (RPE). It has 6 isoforms; the predominant isoform (most common of which) is VEGF 165 and is most linked to neovascularization in the eye. VEGF-A provided the rationale for targeted drug development. Anti-VEGF drugs are anti-angiogenic, anti-inflammatory, antifibrotic, and anti-permeable. The rationale for the use of steroids to treat macular edema is related to their ability to reduce capillary permeability, to inhibit the expression of VEGF gene, and to inhibit the metabolic pathway of VEGF.
Vascular Endothelial Growth Factor A ; Retinal Pigment Epithelium

BACKGROUND: Hemoptysis is an often alarming presenting symptom and VEGF is a major regulator of both normal and abnormal angiogenesis, including many inflammatory diseases. In this report the clinical significance of the serum VEGF level in patients with hemoptysis was investigated. METHODS: Thirty-two patients with hemoptysis were evaluated. The estimated amount of hemoptysis, etiology and serum VEGF level was examined at admission and bronchial angiography was performed in 22 patients. In order to objectify the neovascularization status, one point for the presence of the A-V shunt, hypervascularity, vascular tortuosity was designated for a total of 0-3 points. RESULTS: Mean quantity of hemoptysis was 172.4+/-270.4ml. The mean angiographic neovascularization score was 1.23+/-0.75. The serum VEGF level correlated with the quantity of hemoptysis(r=0.524, p=0.002) and with the angiographic neovascularization score(r=0.441, p=0.04). Using the standard diagnostic criterion for massive hemoptysis, the serum VEGF level of patients with massive hemoptysis(642.4+/-545.6 pg/ml, n=13) was found to be higher than that of patients with non-massive hemoptysis(394.6+/-225.8 pg/ml, n=19)(p=0.069). CONCLUSION: Regardless of the etiology, the serum VEGF may contribute to abnormal neovascularization in patients with hemoptysis. Therefore, it is suggested that serum VEGF measurements may help in predicting a massive hemoptysis.
Angiography ; Hemoptysis* ; Humans ; Vascular Endothelial Growth Factor A*

Objectives This study determined the biologic effect and safety of subconjunctival administration of bevacizumab in patients with primary and recurrent pterygium. Methods We conducted an off-label, multiple-dosing, interventional case series involving 15 patients with primary and recurrent pterygium. They received subconjunctival bevacizumab (1.25 mg) every 2 weeks for 10 weeks. Pterygium vascularity and thickness were graded (1 for atrophic, 2 for intermediate, and 3 for fleshy) by 3 masked observers. The size of the pterygium (measured by surface area in cm2) was recorded from baseline to 16 weeks postinjection. Treatment-related complications and adverse events were reported. The main outcome measures were changes in pterygium size, vascularity, thickness, and treatment safety. Results There was no statistically significant difference in the mean surface area of the pterygia at different intervals (p > 0.05). The mean surface area was 1.22 ± 0.19 cm2 at baseline, 1.22 ± 0.18 cm2 and 1.22 ± 0.17 cm2 at 10 and 16 weeks postinjection respectively. There was a significant difference in the mean pteygium grading by the 3 masked observers at different intervals (p < 0.01). At baseline, there were 11 patients (73.3%) with grade 2 pterygium and 4 (26.7%) with grade 3. At 1.5 months postinjection, there were 5 (33.3%) with grade 1 pterygium, 7 (46.7%) with grade 2, and 3 (20%) with grade 3. The 5 patients with grade 1 pterygium at the end of the study period had a baseline pterygium grading of 2. Snellen visual acuity, refraction, intraocular pressure, and blood pressure remained stable. No serious ocular or systemic side effects were observed. Conclusion Subconjunctival injection of 1.25 mg of bevacizumab given every 2 weeks for 10 weeks resulted in no significant change in size of the pterygium. However, local application of bevacizumab showed promise in inducing regression in pterygium vascularity and thickness. Further evaluation of bevacizumab for the treatment of pterygia is warranted.
Pterygium ; Vascular Endothelial Growth Factor A ; Bevacizumab